ZA985352B - Barbituric acid derivatives with antimetastatic and antitumor activity. - Google Patents

Barbituric acid derivatives with antimetastatic and antitumor activity.

Info

Publication number
ZA985352B
ZA985352B ZA9805352A ZA985352A ZA985352B ZA 985352 B ZA985352 B ZA 985352B ZA 9805352 A ZA9805352 A ZA 9805352A ZA 985352 A ZA985352 A ZA 985352A ZA 985352 B ZA985352 B ZA 985352B
Authority
ZA
South Africa
Prior art keywords
antimetastatic
acid derivatives
antitumor activity
barbituric acid
barbituric
Prior art date
Application number
ZA9805352A
Other languages
English (en)
Inventor
Ambrogio Oliva
Gianpiero De Cillis
Frank Grams
Valeria Livi
Gerd Zimmermann
Ernesto Menta
Hans-Willi Krell
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of ZA985352B publication Critical patent/ZA985352B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA9805352A 1997-06-21 1998-06-19 Barbituric acid derivatives with antimetastatic and antitumor activity. ZA985352B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97110200 1997-06-21

Publications (1)

Publication Number Publication Date
ZA985352B true ZA985352B (en) 1999-12-20

Family

ID=8226939

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9805352A ZA985352B (en) 1997-06-21 1998-06-19 Barbituric acid derivatives with antimetastatic and antitumor activity.

Country Status (18)

Country Link
US (1) US6335332B1 (ko)
EP (1) EP0989982B1 (ko)
JP (1) JP2002504916A (ko)
KR (1) KR20010014020A (ko)
CN (1) CN1295227C (ko)
AR (1) AR018997A1 (ko)
AT (1) ATE302200T1 (ko)
AU (1) AU746853B2 (ko)
BR (1) BR9810450A (ko)
CA (1) CA2294259A1 (ko)
CO (1) CO4940451A1 (ko)
DE (1) DE69831233T2 (ko)
ES (1) ES2247707T3 (ko)
HR (1) HRP980340A2 (ko)
MA (1) MA24573A1 (ko)
TR (1) TR199903148T2 (ko)
WO (1) WO1998058925A1 (ko)
ZA (1) ZA985352B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO190596A0 (en) 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
AUPO937597A0 (en) * 1997-09-24 1997-10-16 Alchemia Pty Ltd Protecting and linking groups for organic synthesis
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
AU2001257230B2 (en) 2000-04-24 2006-09-14 Aryx Therapeutics Ultrashort acting hypnotic barbiturates
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EE200300196A (et) * 2000-10-26 2003-10-15 Pfizer Products Inc. Spiropürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
MXPA03003734A (es) 2000-10-26 2003-07-28 Pfizer Prod Inc Inhibifores de metaloproteinasa del tipo pirimidin-2, 4, 6-triona.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
EP1387689B1 (en) * 2001-05-03 2006-11-02 F. Hoffmann-La Roche Ag Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
CA2480092A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
AU2003223012A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
KR100837137B1 (ko) * 2004-04-01 2008-06-11 에프. 호프만-라 로슈 아게 기관지 염증성 질환의 치료 및 예방을 위한트리옥소피리미딘의 용도
AU2005230379B2 (en) * 2004-04-01 2010-07-22 Universite De Liege Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
HUE036165T2 (hu) 2006-04-07 2018-06-28 Vertex Pharma ATP-kötõ kazetta transzportereinek modulátorai
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
KR100862969B1 (ko) 2007-03-05 2008-10-13 바이오스펙트럼 주식회사 바르비투르산을 유효성분으로 포함하는 피부 미백제
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko) * 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP3104861A4 (en) * 2014-02-14 2017-10-04 Warrell, Raymond P., Jr. Bifunctional compounds and use for reducing uric acid levels
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN107108526A (zh) 2015-01-22 2017-08-29 R·P·小沃勒尔 双功能化合物及用于降低尿酸水平的用途
TWI772309B (zh) 2016-06-30 2022-08-01 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(二)
TWI749024B (zh) 2016-07-06 2021-12-11 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途
LV15384B (lv) 2017-07-24 2019-05-20 Latvijas Organiskās Sintēzes Institūts 1-Acetil-5-nitro-4-fenil-3-pirolin-2-ons pielietošanai vēža ārstēšanā

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3083842B2 (ja) * 1989-11-14 2000-09-04 スローン・ケターリング・インスティテュート・フォー・キャンサー・リサーチ 新規かつ強力な最終分化誘発剤及びその使用方法
ATE155893T1 (de) 1990-05-16 1997-08-15 Abbott Lab Test für barbiturate, tracer, immunogene, antikörper und testsatz dafür
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP0989982A1 (en) 2000-04-05
AU8539198A (en) 1999-01-04
MA24573A1 (fr) 1998-12-31
KR20010014020A (ko) 2001-02-26
AU746853B2 (en) 2002-05-02
CO4940451A1 (es) 2000-07-24
AR018997A1 (es) 2001-12-26
HRP980340A2 (en) 1999-02-28
TR199903148T2 (xx) 2000-04-21
CN1267296A (zh) 2000-09-20
CA2294259A1 (en) 1998-12-30
ATE302200T1 (de) 2005-09-15
ES2247707T3 (es) 2006-03-01
WO1998058925A1 (en) 1998-12-30
DE69831233T2 (de) 2006-06-01
JP2002504916A (ja) 2002-02-12
CN1295227C (zh) 2007-01-17
EP0989982B1 (en) 2005-08-17
US6335332B1 (en) 2002-01-01
DE69831233D1 (de) 2005-09-22
BR9810450A (pt) 2000-09-05

Similar Documents

Publication Publication Date Title
ZA985352B (en) Barbituric acid derivatives with antimetastatic and antitumor activity.
ZA987037B (en) Benzylidene-1-3-dihydro-indol-2-one derivatives having anti-cancer activity.
AU3363499A (en) Nucleosides with antiviral and anticancer activity
PL343249A1 (en) Indole derivatives with antiviral activity
HK1031374A1 (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives.
HK1036408A1 (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity.
ZA9811339B (en) Benzamidine derivatives.
ZA986905B (en) Substituted quinazoline derivatives.
HK1030387A1 (en) Shank fitting structure.
HK1040400A1 (zh) 具有抗腫瘤活性的嘧啶衍生物
HK1022416A1 (en) Wheelchair.
IL125358A0 (en) 5H-thiazolo [3,2-a] pyrimidine derivatives
CY2328B1 (en) 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives having pdeiv and cytokine activity.
GB9522615D0 (en) 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
HUP0102681A3 (en) New guanidine derivatives with anticoagulant activity
MXPA99001777A (es) Dihidropirones con actividad antiviral mejorada.
AU8016398A (en) Peptides with antiviral activity
AU1172599A (en) Compounds with antitumor activity
ZA977833B (en) N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylate inhibitory activity.
ZA989571B (en) 2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use.
HUP0001306A3 (en) Corn pullulanase
ZA986273B (en) Purine derivatives and the use for medicine thereof.
AU7040798A (en) Pyrimidinone-1,3-oxathiolane derivatives with antiviral activity
ZA200006632B (en) Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity.
AU8526198A (en) Compounds with anti-ks and anti-hiv activity